Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

Source :: Business Wire. August 21, 2024
Publication Year :: 2024
Abstract: Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator's choice of lenvatinib or sorafenib in this patient population [...]

Subjects :: United States. Food and Drug Administration
Bristol-Myers Squibb Co.
Ono Pharmaceutical Company Ltd.
Antineoplastic agents
Liver diseases -- Drug therapy
Hepatoma -- Drug therapy
Pharmaceutical industry
Antimitotic agents
Business
Business, international
Yervoy (Medication)
Opdivo (Medication)

Tools